Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sareum Holdings ( (GB:SAR) ) has issued an update.
Sareum Holdings announced that all resolutions were passed during its Annual General Meeting, reflecting shareholder confidence in the company’s strategic direction. This outcome is significant for Sareum as it continues developing its promising kinase inhibitors, which have completed Phase 1 trials, potentially strengthening its position in the biotechnology market.
More about Sareum Holdings
Sareum Holdings is a clinical-stage biotechnology company based in Cambridge, UK, focusing on the development of next-generation kinase inhibitors for autoimmune diseases and cancer. Their lead candidates include SDC-1801, targeting autoimmune diseases such as psoriasis, and SDC-1802, which is aimed at cancer immunotherapy. The company is listed on the AIM market of the London Stock Exchange under the ticker SAR.
YTD Price Performance: -53.78%
Average Trading Volume: 385,721
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £34.31M
Find detailed analytics on SAR stock on TipRanks’ Stock Analysis page.